PPB - Services

Complaints, Feedback and Enquiry

Falsified Soliris identified in WHO regions of the Americas, Europe and South East Asia

[featured_image]
  • Version
  • Download 40
  • File Size 152.40 KB
  • File Count 1
  • Create Date March 21, 2022
  • Last Updated March 21, 2022

Falsified Soliris identified in WHO regions of the Americas, Europe and South East Asia

This WHO Medical Product Alert refers to several batches of falsified Soliris (eculizumab) identified in Argentina, Estonia, India and Uruguay and reported to WHO between November and December 2021. The genuine manufacturer of Soliris, has confirmed that the products listed in this alert are falsified. The falsified products were reported at patient level and regulated supply chains in the above-mentioned countries.

Genuine Soliris is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized Myasthenia Gravis (gMG) in adults, and neuromyelitis optica spectrum disorder (NMOSD).

The products identified in this Alert are confirmed as falsified on the basis that they deliberately/fraudulently misrepresent their identity, composition or source.

Attached Files

FileAction
2021_12_21_N9_2021 Falsified Soliris_EN.pdfDownload

Author

ppb_admin

Leave a comment

Your email address will not be published. Required fields are marked *